Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
Background: This case report presents two clinical cases of metastatic refractory gastrointestinal stromal tumor (GIST) with treatment history of 6–14 years. The follow-up treatment of both cases comprised ripretinib dose escalation and its combination with other tyrosine kinase inhibitors (TKIs). T...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2023-05-01
|
| Серии: | Frontiers in Pharmacology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1122885/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|